Vorolanib is under clinical development by Betta Pharmaceuticals and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II drugs for Thymic Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vorolanib LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vorolanib overview

Vorolanib (Fumena) is an indoline derivative. It is formulated as tablets for oral route of administration. Fumena is indicated for the treatment of advanced renal cell carcinoma.

Vorolanib (X-82) is under development for the treatment of wet age-related macular degeneration, solid tumors including epithelial ovarian adenocarcinoma, metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction, small cell lung cancer, non-small cell lung cancer, thymic carcinoma, pancreatic neuroendocrine tumors, metastatic mucosal melanoma and advanced solid tumors. The drug candidate is administered orally. X-82 is a small molecule indolinone inhibitor of signaling through the growth factor receptors VEGFR and PDGFR.

It was also under development for the treatment of breast cancer, prostate cancer, gastric cancer, hepatocellular carcinoma, fallopian tube cancer, peritoneal cancer, sarcoma and choroidal neovascularization and myopia.

Betta Pharmaceuticals overview

Betta Pharmaceuticals discovers, develops, and supplies drugs for the treatment of cancer and diabetes. Its products include icotinib hydrochloride, an orally administered small-molecule, a reversible tyrosine kinase inhibitor for treating locally advanced or metastatic non-small cell lung cancer; and ensartinib hydrochloride capsules to treat ALK-mutated advanced non-small cell lung cancer. The company has also developed beantine, a macromolecular biological product for the treatment of recurrent non-small lung cancer. Betta Pharmaceuticals is developing its pipeline with small and macromolecule products for multiple cancer treatments. The company operates research and development centers in Hangzhou and Beijing, China and San Diego, the US. Betta Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of Vorolanib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.